Aid, Listerine, Neutrogena, and Johnson's consumer products, reported disappointing Q2 sales and just announced that its CEO ...

Kenvue Inc. closed 13.19% below its 52-week high of $25.17, which the company achieved on May 8th.

Kenvue is expected to release its second-quarter earnings next month, and analysts anticipate a double-digit profit dip.

Kenvue, which was spun off from Johnson & Johnson in 2023, has been working to shore up profitability, especially in its ...

After years of post-COVID-19 normalization and the impact of its Kenvue spinoff, Johnson & Johnson’s (NYSE: JNJ) stock price ...

Experts are raising concerns about Benadryl’s ability to cross the blood-brain barrier and potential lasting impacts.

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

Johnson & Johnson stands alone as a leader across the major healthcare industries. It maintains a diverse revenue base, a developing research pipeline, and exceptional cash flow generation that ...

If you look at the history of the S&P 500 ( ^GSPC -0.40%) index, dividend stocks have played a significant role in ...

Johnson & Johnson ( NYSE: JNJ) Q2 2025 Earnings Conference Call July 16, 2025 8:30 AM ET ...

Asian shares were mostly lower in early Tuesday trading as worries about President Donald Trump’s latest updates to his ...

By Pushkala Aripaka and Emma Rumney (Reuters) -Diageo CEO Debra Crew has stepped down after two years in the job, the world's biggest spirits maker said on Wednesday, with finance chief Nik Jhangiani ...